StocksFundsScreenerSectorsWatchlists
TXG

TXG - 10X Genomics Inc Stock Price, Fair Value and News

34.58USD-1.77 (-4.87%)Market Closed

Market Summary

TXG
USD34.58-1.77
Market Closed
-4.87%

TXG Alerts

  • 1 major insider sales recently.

TXG Stock Price

View Fullscreen

TXG RSI Chart

TXG Valuation

Market Cap

4.1B

Price/Earnings (Trailing)

-16.14

Price/Sales (Trailing)

6.66

EV/EBITDA

-17.63

Price/Free Cashflow

-64.55

TXG Price/Sales (Trailing)

TXG Profitability

Operating Margin

66.15%

EBT Margin

-40.21%

Return on Equity

-34.42%

Return on Assets

-26.43%

Free Cashflow Yield

-1.55%

TXG Fundamentals

TXG Revenue

Revenue (TTM)

618.7M

Rev. Growth (Yr)

17.76%

Rev. Growth (Qtr)

19.74%

TXG Earnings

Earnings (TTM)

-255.1M

Earnings Growth (Yr)

-184.36%

Earnings Growth (Qtr)

47.36%

Breaking Down TXG Revenue

Last 7 days

-4.6%

Last 30 days

-10.2%

Last 90 days

-26.4%

Trailing 12 Months

-36.9%

How does TXG drawdown profile look like?

TXG Financial Health

Current Ratio

4.69

TXG Investor Care

Shares Dilution (1Y)

3.39%

Diluted EPS (TTM)

-2.17

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023536.2M568.4M591.0M618.7M
2022499.2M497.9M503.7M516.4M
2021332.8M405.7M459.2M490.5M
2020264.2M251.3M261.9M298.8M
2019172.5M196.6M221.2M245.9M
201889.9M108.7M127.5M146.3M
201700071.1M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of 10X Genomics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 21, 2024
mcanear justin j.
acquired
-
-
53,312
chief financial officer
Mar 21, 2024
saxonov serge
acquired
-
-
88,854
chief executive officer
Mar 21, 2024
hindson benjamin j.
acquired
-
-
71,083
see remarks
Mar 14, 2024
saxonov serge
gifted
-
-
-1,086
chief executive officer
Mar 04, 2024
saxonov serge
sold
-205,021
43.9959
-4,660
chief executive officer
Feb 22, 2024
hindson benjamin j.
sold
-121,098
46.3443
-2,613
see remarks
Feb 22, 2024
mcanear justin j.
sold
-86,432
46.3443
-1,865
chief financial officer
Feb 22, 2024
saxonov serge
sold
-130,737
46.3443
-2,821
chief executive officer
Feb 15, 2024
saxonov serge
sold
-244,332
48.8664
-5,000
chief executive officer
Feb 09, 2024
saxonov serge
sold
-49,530
49.5301
-1,000
chief executive officer

1–10 of 50

Which funds bought or sold TXG recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 10, 2024
Banque Cantonale Vaudoise
reduced
-28.56
-343,000
315,000
0.01%
Apr 10, 2024
Bruce G. Allen Investments, LLC
unchanged
-
-479
976
-%
Apr 10, 2024
Green Alpha Advisors, LLC
added
1.06
-101,933
214,409
0.16%
Apr 09, 2024
MASSMUTUAL TRUST CO FSB/ADV
reduced
-3.23
-609
1,126
-%
Apr 05, 2024
CWM, LLC
reduced
-19.23
-1,532,000
1,811,000
0.01%
Apr 05, 2024
GAMMA Investing LLC
reduced
-32.07
-13,619
21,467
-%
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
added
5.52
23,210
77,001
-%
Mar 11, 2024
VANGUARD GROUP INC
added
1.21
137,004,000
504,274,000
0.01%
Mar 08, 2024
TRUST CO OF VERMONT
unchanged
-
205
783
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
100
26,425,800
41,731,900
-%

1–10 of 43

Are Funds Buying or Selling TXG?

Are funds buying TXG calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own TXG
No. of Funds

Unveiling 10X Genomics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
8.65%
9,011,332
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 31, 2024
blackrock inc.
5.5%
5,705,051
SC 13G/A
Jan 29, 2024
baillie gifford & co
7.60%
7,919,976
SC 13G/A
Dec 08, 2023
morgan stanley
3.5%
3,630,398
SC 13G/A
Jul 10, 2023
morgan stanley
5.2%
5,139,461
SC 13G/A
Jul 10, 2023
fmr llc
-
0
SC 13G/A
Feb 14, 2023
venrock associates vi, l.p.
4.9%
4,828,247
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
8.81%
8,420,011
SC 13G/A

Recent SEC filings of 10X Genomics Inc

View All Filings
Date Filed Form Type Document
Apr 12, 2024
PRE 14A
PRE 14A
Mar 25, 2024
4
Insider Trading
Mar 25, 2024
4
Insider Trading
Mar 25, 2024
4
Insider Trading
Mar 18, 2024
4
Insider Trading
Mar 06, 2024
4
Insider Trading
Mar 04, 2024
144
Notice of Insider Sale Intent
Feb 26, 2024
4
Insider Trading
Feb 26, 2024
4
Insider Trading
Feb 26, 2024
4
Insider Trading

Peers (Alternatives to 10X Genomics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
404.6B
371.6B
-10.06% -16.60%
18.08
1.09
14.64% 11.24%
102.3B
195.3B
0.36% 32.66%
19.05
0.52
8.17% -20.79%
86.4B
357.8B
-8.56% -8.98%
10.34
0.24
10.95% 93.52%
85.4B
65.0B
0.28% 18.07%
16.29
1.31
7.86% -7.11%
37.8B
154.0B
-7.79% 1.99%
14
0.25
6.54% 124.79%
11.6B
14.3B
-4.37% 22.44%
16.11
0.81
6.59% 6.24%
11.4B
12.1B
-5.66% 54.55%
16.54
0.94
4.57% 23.40%
MID-CAP
9.4B
2.3B
-4.31% 9.94%
34.32
4.13
6.06% 9.17%
6.8B
2.9B
-6.65% -2.97%
-311.58
2.31
12.20% -107.93%
2.3B
1.4B
-0.51% 1.54%
37.23
1.63
21.19% 34.42%
2.1B
3.8B
-4.61% -35.19%
10.19
0.57
-27.73% -52.50%
SMALL-CAP
1.6B
1.1B
-1.23% -12.42%
25.41
1.5
11.31% 35.83%
1.2B
3.0B
4.69% 55.53%
-6.48
0.41
6.74% 20.73%
51.1M
-
-15.28% -9.77%
-3.49
-
- -12.94%
18.5M
21.3M
10.98% 5.02%
34.8
0.87
8.00% -62.25%

10X Genomics Inc News

Latest updates
Defense World11 Apr 202409:00 am
MarketBeat10 Apr 202403:53 pm
Nasdaq14 Mar 202407:00 am
Seeking Alpha15 Feb 202408:00 am

10X Genomics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue19.7%183,979,000153,644,000146,819,000134,285,000156,232,000131,072,000114,609,000114,496,000143,530,000125,297,000115,842,000105,821,000112,218,00071,817,00042,905,00071,905,00075,289,00061,207,00055,819,00053,578,00050,554,000
Cost Of Revenue17.3%68,197,00058,115,00047,207,00035,895,00036,827,00030,377,00027,704,00025,478,00027,598,00024,518,0004,915,00017,060,00018,897,00014,411,00010,052,00015,108,00016,582,00015,480,00015,006,00013,965,000-
Gross Profit21.2%115,782,00095,529,00099,612,00098,390,000119,405,000100,695,00086,905,00089,018,000115,932,000100,779,000110,927,00088,761,00093,321,00057,406,00032,853,00056,797,00058,707,00045,727,00040,813,00039,613,00035,654,000
Operating Expenses-10.2%170,970,000190,324,000162,970,000150,378,000142,501,000140,691,000150,022,000130,753,000131,762,000116,658,000121,255,00098,977,000502,904,000122,661,00072,273,00076,681,00066,787,00054,823,00051,175,00042,648,000-
  S&GA Expenses4.5%86,125,00082,415,00091,510,00083,280,00078,887,00073,401,00079,337,00066,675,00069,877,00062,076,00068,703,00056,904,00055,974,00051,549,00044,416,00050,387,00038,756,00032,614,00032,571,00026,893,000-
EBITDA Margin-9.4%-0.34-0.31-0.24-0.27-0.26-0.27-0.23-0.12-0.06-0.93-1.17-1.53-1.74-0.45-0.25-0.14-0.08-0.41-0.50-0.62-0.73
Interest Expenses700.0%8,0001,0005,00019,000125,000114,000109,000128,000217,000219,000209,000221,000317,000397,000306,000662,000992,000708,000695,000684,000-
Income Taxes89.5%2,354,0001,242,0001,647,0001,093,000804,0001,879,000627,000719,0002,456,000523,0001,094,000435,0006,949,000585,000422,000300,000108,0008,00068,00034,000-
Earnings Before Taxes49.2%-46,598,000-91,744,000-60,767,000-49,654,000-16,411,000-40,035,000-63,831,000-41,694,000-15,993,000-16,648,000-9,958,000-11,116,000-408,623,000-65,263,000-39,745,000-20,845,000-7,026,000-9,595,000-10,810,000-3,602,000-
EBT Margin-8.7%-0.40-0.37-0.29-0.32-0.31-0.32-0.28-0.17-0.11-0.97-1.22-1.58-1.79-0.51-0.31-0.18-0.13-0.45-0.54-0.65-0.77
Net Income47.4%-48,952,000-92,986,000-62,414,000-50,747,000-17,215,000-41,914,000-64,458,000-42,413,000-18,449,000-17,171,000-11,052,000-11,551,000-415,573,000-65,848,000-40,167,000-21,143,000-7,134,000-9,603,000-10,878,000-3,636,000-75,524,000
Net Income Margin-9.1%-0.41-0.38-0.30-0.33-0.32-0.33-0.29-0.18-0.12-0.99-1.24-1.60-1.82-0.51-0.31-0.18-0.13-0.45-0.54-0.58-0.77
Free Cashflow155.0%22,308,000-40,540,000-36,882,000-8,684,000-26,011,000-46,136,000-44,182,000-48,938,000-21,813,000-46,443,000-11,448,000-42,947,000-151,514,000-56,138,000-36,257,000-10,655,000144,000848,000-9,058,000-49,000-53,403,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32018Q4
Assets1.8%9659499901,0141,0299961,0021,0031,0199919789549291,04358361046.00573124
  Current Assets6.0%596562583602635629666697748744757746774900452430481474106
    Cash Equivalents14.2%35931533134022724228232059660964964468983440443247647770.00
  Inventory-8.9%74.0081.0084.0082.0082.0079.0071.0064.0060.0051.0044.0039.0030.0025.0022.0019.0015.0013.009.00
  Net PPE-1.9%28028528529228925822319016914312210773.0065.0056.0052.0049.0047.0011.00
  Goodwill0%5.005.005.005.005.005.005.005.005.005.005.005.005.00------
Liabilities10.2%22420319621222322021819720119019320219021719220178.00151101
  Current Liabilities21.4%12710598.0011213112711894.0011010011312111814612259.0063.0048.0032.00
  Long Term Debt-----------------20.0022.0025.00
    LT Debt, Current-----------------10.007.004.00
    LT Debt, Non Current-----------------20.0022.0025.00
Shareholder's Equity-0.6%741745793802806776784807818800785752739825391409420421-
  Retained Earnings-4.0%-1,284-1,235-1,142-1,080-1,029-1,012-970-905-863-844-827-816-805-389-323-283-262-255-231
  Additional Paid-In Capital2.2%2,0261,9811,9371,8841,8391,7931,7581,7151,6811,6451,6121,5691,5441,21571569368267711.00
Accumulated Depreciation10.2%10394.0086.00-69.00---49.0044.0039.0035.0031.00---19.00-14.00
Shares Outstanding1.2%11911811611611511411311311011110910910110198.0097.0039.0029.0013.00
Float---5,700---4,500---18,700---7,300----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations201.8%25,758-25,304-11,526-4,12513,723-9,564-16,963-20,8025,805-26,2163,120-4,082-130,175-55,629-29,518-2,5766,70014,5264,0839,318-
  Share Based Compensation-3.3%38,91840,23545,69642,10140,97433,51436,31326,04726,90425,95026,93216,17614,26913,78413,8556,7185,0753,8743,0251,359-
Cashflow From Investing167.3%13,0984,900-4,462119,956-33,172-32,630-27,527-257,558-27,618-20,227-14,568-44,316-22,266-1,310-6,739-8,079-6,581-13,678-13,141-9,367-
Cashflow From Financing28.3%5,6134,3747,096-3,4145,0012,0396,3602,4178,9036,68316,1933,5187,706486,9688,051-33,819-1,107415,638-864923-

TXG Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Revenue$ 618,727$ 516,409$ 490,490
Cost of revenue209,414120,38674,091
Gross profit409,313396,023416,399
Operating expenses:   
Research and development270,332265,667211,752
In-process research and development60,98000
Selling, general and administrative343,330298,300257,560
Accrued contingent liabilities00(660)
Total operating expenses674,642563,967468,652
Loss from operations(265,329)(167,944)(52,253)
Other income (expense):   
Interest income16,9066,647206
Interest expense(33)(476)(866)
Other expense, net(307)(198)(802)
Total other income (expense)16,5665,973(1,462)
Loss before provision for income taxes(248,763)(161,971)(53,715)
Provision for income taxes6,3364,0294,508
Net loss$ (255,099)$ (166,000)$ (58,223)
Net loss per share, basic (in dollars per share)$ (2.18)$ (1.46)$ (0.53)
Net loss per share, diluted (in dollars per share)$ (2.18)$ (1.46)$ (0.53)
Weighted-average shares used to compute net loss per share, basic (in shares)117,165,036113,858,684110,347,937
Weighted-average shares used to compute net loss per share, diluted (in shares)117,165,036113,858,684110,347,937

TXG Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 359,284$ 219,746
Marketable securities29,411210,238
Restricted cash02,633
Accounts receivable, net114,832104,211
Inventory73,70681,629
Prepaid expenses and other current assets18,78916,578
Total current assets596,022635,035
Property and equipment, net279,571289,328
Restricted cash04,974
Operating lease right-of-use assets65,36169,882
Goodwill4,5114,511
Intangible assets, net16,61622,858
Other noncurrent assets3,0622,392
Total assets965,1431,028,980
Current liabilities:  
Accounts payable15,73821,599
Accrued compensation and related benefits30,10532,675
Accrued expenses and other current liabilities56,64859,779
Deferred revenue13,1507,867
Operating lease liabilities11,5219,037
Total current liabilities127,162130,957
Operating lease liabilities, noncurrent83,84986,139
Deferred revenue, noncurrent8,8143,165
Other noncurrent liabilities4,2752,976
Total liabilities224,100223,237
Commitments and contingencies (Note 7)
Stockholders' equity:  
Preferred stock, $0.00001 par value; 100,000,000 shares authorized, no shares issued or outstanding as of December 31, 2023 and 202200
Common stock, $0.00001 par value; 1,100,000,000 shares authorized (Class A 1,000,000,000, Class B 100,000,000); 119,095,362 (Class A 105,038,529, Class B 14,056,833) and 115,195,009 (Class A 96,527,754, Class B 18,667,255) shares issued and outstanding as of December 31, 2023 and 2022, respectively22
Additional paid-in capital2,025,8901,839,397
Accumulated deficit(1,284,420)(1,029,321)
Accumulated other comprehensive loss(429)(4,335)
Total stockholders’ equity741,043805,743
Total liabilities and stockholders’ equity$ 965,143$ 1,028,980
TXG
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
 CEO
 WEBSITE10xgenomics.com
 INDUSTRYHealthcare Plans
 EMPLOYEES1243

10X Genomics Inc Frequently Asked Questions


What is the ticker symbol for 10X Genomics Inc? What does TXG stand for in stocks?

TXG is the stock ticker symbol of 10X Genomics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of 10X Genomics Inc (TXG)?

As of Fri Apr 12 2024, market cap of 10X Genomics Inc is 4.12 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TXG stock?

You can check TXG's fair value in chart for subscribers.

What is the fair value of TXG stock?

You can check TXG's fair value in chart for subscribers. The fair value of 10X Genomics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of 10X Genomics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TXG so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is 10X Genomics Inc a good stock to buy?

The fair value guage provides a quick view whether TXG is over valued or under valued. Whether 10X Genomics Inc is cheap or expensive depends on the assumptions which impact 10X Genomics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TXG.

What is 10X Genomics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 12 2024, TXG's PE ratio (Price to Earnings) is -16.14 and Price to Sales (PS) ratio is 6.66. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TXG PE ratio will change depending on the future growth rate expectations of investors.